Northwestern University Feinberg School of Medicine

Department of Physical Medicine & Rehabilitation

Clinical Trials

Clinica research under the direction of the Department of Physical Medicine and Rehabilitation is conducted through Northwestern University Feinberg School of Medicine. Below you'll find our current clinical trial, including investigator and contact information.

Find additional clinical trials information related to physical medicine and rehabilitation via the Rehabilitation Institute of Chicago website's Research Studies & Clinical Trials section.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

Trials
A Study to Show That Treatment With Denosumab is as Good as Treatment With Risedronate in Subjects Who Are Starting to Take or Currently Taking Glucocorticoids.
This study is being conducted in patients taking glucocorticoids for treatment of various diseases. It is a 2-year study that will compare t…
This study is being conducted in patients taking glucocorticoids for treatment of various diseases. It is a 2-year study that will compare the effects of denosumab and risedronate.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT01575873 STU00062724
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inf…
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02528188 STU00201068
More Info

For more information on this study please contact us:

Rankin, Katherine 312 503 4043
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the …
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT02528253 STU00201593
More Info

For more information on this study please contact us:

Rankin, Katherine 312 503 4043
A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain…
The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS). Secondary objectives of the study are to evaluate the efficacy of fasinumab compared to placebo as measured by: - Change from baseline in the Roland Morris disability questionnaire (RMDQ) total score - Change from baseline in the Patient Global Assessment (PGA) of Low Back Pain (LBP) score - Change from baseline in the average daily LBPI NRS score
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02620020 STU00202182
More Info

For more information on this study please contact us:

1-855-NU-STUDY
COAST-1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.
This study…
This study is designed to determine the efficacy and safety of Disodium Zoledronate Tetrahydrate in reducing pain in subjects with knee osteoarthritis. Males of 50 years of age or older and post-menopausal females with knee pain or newly diagnosed osteoarthritis of the knee may be eligible to participate.
Males of 50 years of age or older and post-menopausal women may be eligible to participate.
Schnitzer, Thomas JSchnitzer, Thomas J
  • Map it 710 N. Lake Shore Dr. Abbott Hall
    Chicago, IL
NCT02746068 STU00202310
More Info

For more information on this study please contact us:

Marks, Julia 312 503 1215
A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02504008 STU00202307
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Approximately 10,000 patients will participate in this study to further characterize the safety profile of fasinumab and provide data on long-term exposure to provide…
Approximately 10,000 patients will participate in this study to further characterize the safety profile of fasinumab and provide data on long-term exposure to provide efficacy data. In addition to their participation in the main study, approximately 800 patients will participate in a sub-study to characterize the onset of pain relief by fasinumab.
At least 18 yrs of age, BMI 39 or less, Osteoarthritis of the knee or hip, taking either Acetaminophen/Tylenol, NSAIDs or opioids at least 4 days a week over last month, fails (either inadequate pain relief, unable to take or refuses to take) Acetaminophen/Tylenol, NSAIDs, and opioids, no rheumatoid arthritis, no fibromyalgia, no symptoms of carpal tunnel syndrome in last 6 months, able to undergo an MRI, is not scheduled for a joint replacement in the next 1.5 yrs, no HIV, no Hepatitis, no sickle cell disease, no S-C disease, no S-beta thalassemia, no heart block, no cancer in last 5 yrs, no hospitalization for depression in last 5 yrs, no alcohol or substance abuse in last 5 yrs, no marijuana use for pain relief in last 6 months, if a female must not become pregnant or breastfeed during the study, and if a female of child-bearing potential must be willing to use contraception during study.
Schnitzer, Thomas JSchnitzer, Thomas J
NCT02683239 STU00202672
More Info

For more information on this study please contact us:

Coello, Alexandra 312 503 4535